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RATE OF DELINE OF RABBIT ANTI-THYMOCYTE GLOBLULIN (RATG)
SERUM LEVELS IN CHILDREN IS RELATED TO IMMUNE RECONSTITU-
TION AND CHIMERISM STATUS AFTER REDUCED-INTENSITY ALLOGE-
NEIC TRANSPLANTATION
Horn, B.N.1, O’Brien, S.1, Hwang, J.1, Oon, C.Y.1, Cowan, M.J.1
1UCSF, San Francisco, CA.
We measured rabbit antithymocyte globulin levels until 6
months after hematopoietic stem cell transplantation (HSCT)
in 14 children undergoing reduced intensity conditioning (RIC)
and HSCT and in 4 patients receiving haploidentical T-cell
depleted transplants for malignant and non-malignant disor-
ders. Twelve patients received 8mg/kg of rATG, and 6 patients
received 3.5-4.5 mg/kg of rATG. The majority of patients
(72%) underwent unrelated or mismatched transplants. At four
years post transplant, overall survival and event-free survival
were 839% and 7210.6%, respectively; however, the en-
graftment failure rate was high (23%).
Serum active and total rATG levels cleared to subtherapeutic
levels (1 g/ml) by 2 and 16 weeks post transplant, respectively.
CMV reactivation occurred in 54% of patients at risk, and EBV
infection occurred in 22% of patients. Infections were treated
successfully, except in patients with graft failure. Acute and chronic
graft-versus host disease developed in 40% of patients.
Patients who recieved 8 mg/kg of rATG were further divided in
two groups based on the rate of decline of serum total rATG levels.
Five patients were in the group with the slow rate of decline and 6
patients in the group with fast rate of decline of total rATG.
Patients with slow rATG clearance took longer to recover all
lymphocyte subsets and B- and T-cell function; however, statistical
signiﬁcance was reached only for CD8 subset, isohemagglutinin
titer and IgM levels. We also found that the rate of decline of total
rATG level was associated with chimerism status at 1-year post
transplant. Of 4 patients with a fast rATG decline, 3 had full donor
chimerism and 1 mixed donor chimerism at one year post trans-
plant; all 4 patients with a slow decline of rATG were mixed
chimeras at 1-year post transplant (p for Fisher exact0.03). How-
ever, graft loss was not associated with the rate of decline of rATG.
Conclusion: The use of rATG in children results in low inci-
dence of GVHD, but does not decrease the risk of graft rejection.
rATG clearance in children is heterogenous, and the rate of elim-
ination of rATG may play a role in immune reconstitution and
chimerism after reduced intensity transplants. Understanding the
pharmacokinetics and causes of individual variations in the clear-
ance of rATG may lead to more efﬁcacious use of this potent
immunosuppreessive medication.
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UNRELATED CORD BLOOD TRANSPLANTATION (UCBT) FOR TRANSFU-
SION-DEPENDENT THALASSEMIA – A RETROSPECTIVE AUDITED ANAL-
YSIS OF 41 CONSECUTIVE PATIENTS
Jaing, T.-H.1, Tan, P.2, Rosenthal, J.3, Chan, L.L.4, Lin, H.-P.5,
Tan, P.-L.6, Nademanee, A.3, Karanes, C.3, Gjertson, D.7, Wang, B.8,
Petz, L.8, Chow, R.8,9,10 1Chang Gung Children’s Hospital & Univer-
sity, Linkou, Taiwan; 2Mount Elizabeth Hospital, Singapore; 3City of
Hope National Medical Center, Duarte, CA; 4University of Malaya
Medical Center, Kuala Lumpur, Malaysia; 5Subang Jaya Medical Cen-
ter, Malaysia; 6National University Hospital, Singapore; 7UCLA School
of Public Health, Los Angeles, CA; 8StemCyte International Cord Blood
Center, Arcadia, CA; 9StemCyte Taiwan National Medical Center,
Linkou, CA; 10StemCyte Research Institute, Arcadia, CA.
UCBT offers a cure for thalassemia and CB has advantages as
a stem cell source for minorities, where thalassemia is prevalent.
Previously mortality risks outweigh beneﬁts and cell dose is
critical for UCBT. With strategies that maximize cell dose -
using non-red cell reduced plasma depleted (PD) CB, no post-
thaw wash (NW), and double cord transplantation (DCT),
promising results may be achieved with UCBT in selected
thalassemics. Between 7/01 and 9/06, 47 UCBT were performed
after myeloablative therapy in 41 pediatric patients with thalas-
semia major (7 DCT & 1 re-transplant) at 14 transplant centers
(TC) using 81% PD CB with 91% NW. Patient status: 19
Pesaro class 1, 4 class 2, 1 class 3, and 17 status unknown. The
median age was 5 yo (range 0.3-20 yo) with a median weight of
18 kg (range 8-45 kg). The data was audited by external agen-
cies. No signiﬁcant adverse events were observed despite major
ABO incompatibility in some cases. Kaplan-Meier estimates of
ANC500, platelet 20K and platelet 50K engraftment rate with
donor chimerism were 866%, 748% and 768%, and me-
dian times to ANC500, platelet 20K and platelet 50K engraft-
ment were 16 days (range 11-32), 38 days (range 16-99) and 57
days (range 30-106) after transplantation respectively. 7 patients
died with 2 deaths prior to day 20 and one traumatic head injury.
32 patients are known to be alive, no survival data for 2 patients,
5 with autologous recovery, and 34 engrafted with a mean and
median follow up time of 440 and 243 days respectively (range
8-1,750 days) as of 9/18/2006. Median day to hospital discharge
was day 64 (range 22-121 days). Experienced TC (5 cases of
UCBT for thalassemia) were compared with less experienced
TC, and CB that were post-thaw washed were compared with
CB that were NW. Results appear to show improvement with
TC experience and NW. The role of plasma depletion vs. RBC
depletion was studied by matching age, weight, TNC dose,
#HLA matches, conditioning regimen, TC experience, and NW
status between the two groups , and results trended towards
improvements in engraftment and DFS for PD CB. To our
knowledge, this is the largest multi-institutional UCBT series
for thalassemia and demonstrate that UCBT may be a promising
approach for the curative therapy of thalassemia major and
engraftment of 936% and 1-year DFS of 888% are attain-
able with experience and judicious patient selection when cell
dose is optimized with PD CBU, no post-thaw wash and DBT
when necessary.
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RELAPSE FOLLOWING BUSULFAN/CYCLOPHOSPHAMIDE CONDITION-
ING IN CHILDREN AND ADOLESCENTS UNDERGOING HLA-IDENTICAL
SIBLING TRANSPLANTATION FOR STABLE PHASE CHRONIC MYELOID
LEUKEMIA
Lehmann, L.E.1,2, Buonanno, M.1,2, Duncan, C.N.1,2 1Dana Farber
Cancer Institute, Boston, MA; 2Children’s Hospital Boston, Boston, MA.
Chronic Myelogenous Leukemia (CML) while primarily a
disease of adults accounts for up to 5% of childhood leukemias.
Allogeneic hematopoietic stem cell transplant (HSCT) remains
the only curative modality and is recommended for children and
adolescents particularly if a matched sibling donor is available.
Cyclophosphamide (CY) and busulfan (Bu) have been shown to
be an effective conditioning regimen for CML in the setting of
a HLA-matched related donor whereas total body irradiation
(TBI) based regimens are usually used if the donor is unrelated.
Bu/CY is an attractive approach,especially in younger patients,
as it has less effect on growth as well as less risk of secondary
malignancies, thyroid dysfunction and cataract formation. From
1995 through 2005 we transplanted 9 children and adolescents
from matched sibling donors in the ﬁrst stable phase of CML.
The median ages of the patients and donors at transplant were
13 (range 1-18) years and 12 (2-21 )years. All patients went to
HSCT within 4 mos of diagnosis. 3 patients (transplanted be-
fore 7/01) received only hydroxyurea (HU) pre-SCT and CY/
TBI for conditioning. These patients have 100% leukemia-free
survival and none have chronic graft versus host disease
(GVHD). The remaining 6 children were conditioned with
Bu/CY , with targeted Bu levels in 5/6. 3 received imatinib
pre-HSCT, 2 received HU alone and one received no CML-
directed therapy. 5 of these 6 children (83%) have relapsed
following HSCT. 1 relapsed into lymphoid blast crisis 11
months post-HSCT; he is now 2 yrs post- unrelated donor
HSCT in molecular remission (MR) with limited chronic
GVHD . 4 of the 6 experienced molecular relapses at a median
time of 20 (range 9-22 ) months post-HSCT. All received donor
lymphocye infusions (DLI) (2 patients received DLI x1, 2 pa-
tients required DLI x3 with increasing T-cell dose) and re-
attained molecular remission within 3 months of the last DLI. 1
has limited fasciitic chronic GVHD , 1 has oral GVHD and 2
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